Mankind Pharma Interview : Jobs in QA, QC, Production
4 August 2026

Mankind Pharma Interview : Jobs in QA, QC, Production

HPLC & GC operation Empower Software Wet Lab Analysis UV IR SOR LOD AIT KF BD FTIR PSD SA etc. Automated instrument operation. Mankind Pharma Interview, M.Pharm, B.Pharm, M.Sc, B.Sc
Openings in Quality Assurance and Quality Control at IPCA Labs
4 August 2026
Openings in Quality Assurance and Quality Control at IPCA Labs
B.Pharm | M.Pharm | B.Sc | BA | ITI | D.Pharma B.Com | M.Com, Ipca Labs
Pharma and Chemistry Jobs in API and Formulation Plants at Cohance Lifesciences
4 August 2026
Pharma and Chemistry Jobs in API and Formulation Plants at Cohance Lifesciences
Liquid filling, Packing, Compression, Granulation, Capsule Filling, Coating & Encapsulation
Accenture looking for Life Science Regulatory Svs Analyst
4 August 2026
Accenture looking for Life Science Regulatory Svs Analyst
In this role you are required to do analysis and solving of lower-complexity problems. Your day to day interaction is with peers within Accenture before updating supervisors.
Work as Quality & Regulatory Affairs Manager at Baxter
4 August 2026
Work as Quality & Regulatory Affairs Manager at Baxter
Establish strong relationship with country regulatory authorities to facilitate technical and strategic discussions related to product. Baxter
Wipro Limited Hiring First Line Manager
4 August 2026
Wipro Limited Hiring First Line Manager
Conduct briefings before every shift to drive focus on key metrices and debrief at the end of the shift to drive focus of the team on quality and adherence to contract compliance processes
Apply Online for Associate Medical Writer at Thermo Fisher Scientific
4 August 2026
Apply Online for Associate Medical Writer at Thermo Fisher Scientific
Assists with researching, writing, and editing routine documents including Informed consent forms, Lay summaries, and other patient centric documents.
Amgen Reports Material Cybersecurity Incident After Unauthorized Access to Cloud Data
4 August 2026
Amgen Reports Material Cybersecurity Incident After Unauthorized Access to Cloud Data

Amgen Inc. has disclosed a material cybersecurity incident after identifying unauthorized activity involving data stored in cloud environments hosted by third-party service providers. The company revealed the incident in a Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (SEC).

According to the filing, Amgen detected the unauthorized activity in July 2026 and immediately activated its cybersecurity incident response plan. The company implemented containment measures and engaged independent cybersecurity forensic experts to investigate the breach.

Sandoz Moves to Resolve Legacy U.S. Generic Drug Litigation with Nearly 480 Million USD Settlement
4 August 2026
Sandoz Moves to Resolve Legacy U.S. Generic Drug Litigation with Nearly 480 Million USD Settlement

Sandoz has announced significant progress in resolving long-standing U.S. litigation related to the generic medicines market, entering into settlement agreements covering the majority of its remaining legacy antitrust cases in the United States. The company stated that the agreements are intended to resolve historical legal disputes while allowing it to remain focused on its core business of expanding access to affordable medicines.

Dr. Reddy’s Wins U.S. FDA Approval for Rituximab Biosimilar, Strengthening Global Biologics Presence
4 August 2026
Dr. Reddy’s Wins U.S. FDA Approval for Rituximab Biosimilar, Strengthening Global Biologics Presence

Dr. Reddy’s Laboratories has received approval from the U.S. Food and Drug Administration (FDA) for its rituximab biosimilar, a biosimilar version of Rituxan® (rituximab), marking another significant milestone in the company's expanding global biosimilars business.

The approval enhances Dr. Reddy’s biologics portfolio and reinforces its presence in the highly regulated U.S. pharmaceutical market. The biosimilar was developed, manufactured, and submitted for approval entirely by Dr. Reddy’s Laboratories.